Bracco Diagnostics Inc. (“Bracco”) offers products and services to healthcare professionals. Its contrast imaging agents and medical devices for use by healthcare professionals are regulated by the Food and Drug Administration in the United States.
This Website has been developed as a service of Bracco. Like any other service, in spite of our best efforts the information in this Website may become out of date over time. Unless otherwise indicated, the information contained in this site is for medical professionals only. Nothing on this Website should be construed as the giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action.
Bracco accepts no liability for the accuracy or completeness or use of, nor any liability to update, the information contained on this Website.
These materials are provided “AS IS” WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT.
This U.S.-based Website may link you to other Websites on the Internet, including the Websites for Bracco affiliates in other countries. Bracco cannot take responsibility for information found on third party Websites outside its control. While Bracco attempts to provide links only to third-party Websites that comply with all applicable laws and regulations and Bracco’s standards, please understand that the content on these third-party Websites is subject to change without notice to Bracco. We therefore cannot be responsible for, and accept no liability for, any information or opinion contained in any third-party Website.
Any personally identifiable information in electronic communications to this Website is governed by this site’s Privacy Policy. The owners of this Website shall be free to use or copy all other information in any such communications, including any ideas, inventions, concepts, techniques or know-how disclosed therein, for any purposes. Such purposes may include disclosure to third parties and/or developing, manufacturing and/or marketing goods or services.
The sender of any communications to this Website or otherwise to the owners of this site shall be responsible for the content and information contained therein, including its truthfulness and accuracy.
Copyright and Intellectual Property
Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent or trademark of Bracco or any third party.
Except as expressly provided above, nothing contained herein shall be construed as conferring any license or right under any Bracco copyright.
Trademarks and service marks owned by or licensed to Bracco are presented as italicized typefaces. Bracco claims no ownership in, nor any affiliation with, any third-party trademarks appearing in this Website. Such third-party trademarks are used only to identify the products and services of their respective owners, and no sponsorship or endorsement on the part of Bracco should be inferred from the use of these marks.
Should any viewer of a Bracco published document respond with information including feedback data such as questions, comments, suggestions, or the like regarding the content of any such Bracco material, such information shall be deemed to be non-confidential and we shall have no obligation of any kind with respect to such information and shall be free to reproduce, use, disclose, and distribute the information to others without limitation.
We shall be free to use any ideas, concepts, know-how or techniques contained in such information for any purpose whatsoever including but not limited to developing, manufacturing and marketing products incorporating such information.
LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use
Indications
LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use is an ultrasound contrast agent indicated for use:
IMPORTANT SAFETY INFORMATION
WARNING: SERIOUS CARDIOPULMONARY REACTIONS
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres. Most serious reactions occur within 30 minutes of administration.
Contraindications
LUMASON (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use is contraindicated in patients with known or suspected hypersensitivity to sulfur hexafluoride lipid microsphere or its components, such as polyethylene glycol (PEG).
Warnings
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or shortly following administration of ultrasound contrast agents, including LUMASON. Always have cardiopulmonary resuscitation personnel and equipment readily available prior to LUMASON administration and monitor all patients for acute reactions.
Post-marketing hypersensitivity reactions, including serious hypersensitivity reactions, have been observed during use or shortly following LUMASON administration. These reactions may occur in patients with no history of prior exposure to sulfur hexafluoride lipid-containing microspheres. LUMASON contains PEG. There may be increased risk of serious reactions including death in patients with prior hypersensitivity reaction(s) to PEG.
Systemic embolization may occur in patients with cardiac shunts. Assess patients with cardiac shunts for embolic phenomena following LUMASON administration.
There is a risk of ventricular arrhythmia related to high mechanical index in patients administered LUMASON. LUMASON is not recommended for use at mechanical indices greater than 0.8.
The most common adverse reactions (incidence ≥ 0.5%) are headache (1%) and nausea (0.5%).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please click here for full Prescribing Information for LUMASON ultrasound contrast agent, including BOXED WARNING on Serious Cardiopulmonary Reactions.
LUMASON is manufactured for Bracco Diagnostics Inc., Monroe Township, NJ 08831 by Bracco Suisse S.A., Plan-les-Ouates Geneve, Switzerland (LUMASON lyophilized powder vial-25 mg lipid-type A/60.7 sulfur hexafluoride gas); Vetter Pharma-Fertigung GmbH & Co. KG, 88212 Ravensburg, Germany (Sodium Chloride 0.9% Injection, USP); B. Braun Melsungen AG, 34212 Melsungen, Germany (Mini-Spike).
LUMASON is a registered trademark of Bracco Diagnostics Inc.
Bracco Diagnostics Inc.
259 Prospect Plains Road, Building H
Monroe Township, NJ 08831 USA
Phone: 609-514-2200
Toll Free: 1-877-272-2269 (U.S. only)
Fax: 609-514-2446
© 2022 Bracco Diagnostics Inc. All Rights Reserved. US-LUM-2000052 06/21
IMPORTANT SAFETY INFORMATION | INDICATIONS AND USAGE
LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use
IMPORTANT SAFETY INFORMATION
WARNING: SERIOUS CARDIOPULMONARY REACTIONS
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres. Most serious reactions occur within 30 minutes of administration.